Anti phospho chk1 ser345 antibody

Anti-phospho-Chk1-Ser317 antibody (1:1000, 12302), anti-phospho-Chk1-Ser345 antibody (1:10002348), and anti-Rb antibody (1:500, 9309) were purchased from Cell Signaling Technology (CST, Danvers, Massachusetts, US). Anti-CENPF antibody (1:1000, DF2310), anti-Chk1 antibody (1:1000, AF6007), anti-E2F1 antibody (1:500, DF6797) and anti-GAPDH antibody (1:3000, AF7021) were purchased from Affinity Biotech (Cincinnati, Ohio, US). Anti-CENPF antibody (1:1000, ab5) was purchased from Abcam (Cambridge, UK).

Immunoblotting analysis was performed as reported previously^{62 (link)}. The collected cells and tissue samples were homogenized on ice with M-PER and T-PER buffer (Thermo Fisher Scientific, Inc.), respectively. Proteins were separated by SDS-PAGE and analyzed by Western blotting. Anti-Chk1 antibody (#2360), anti-Phospho-Chk1 (Ser345) antibody (#2348), anti-Cleaved PARP antibody (#5625), anti-Cleaved Caspase-3 antibody (#9661), anti-β-Actin antibody (#4967), HRP-conjugated anti-rabbit IgG antibody (#7074), and HRP-conjugated anti-mouse IgG antibody (#7076) were obtained from Cell Signaling Technology, Inc. Anti-phospho-RPA2 (Thr21) antibody (#ab61065) and anti-RRM1 antibody (#ab137114) were obtained from Abcam plc. Anti-SLFN11 antibody (#sc515071) and anti-RRM2 antibody (#sc10844) were obtained from Santa Cruz Biotechnology, Inc. Anti-RPA2 antibody (#NA19L), anti-phospho-RPA2 (Ser4/Ser8) antibody (#A300-245A), and anti-γH2AX antibody (#613402) were obtained from Merck KGaA, Bethyl Laboratories, Inc., and BioLegend, Inc., respectively. The signals were detected with the ImageQuant LAS 4010 (GE Healthcare UK Ltd.).